Sitagliptin repositions a diabetes drug against gemcitabine-resistant pancreatic cancer
Gemcitabine resistance has long defined the therapeutic ceiling in pancreatic ductal adenocarcinoma, where survival in advanced disease has remained dismal despite aggressive chemotherapy. A phase 2 study now places a familiar diabetes drug, sitagliptin, into that resistance problem with an unusually specific biologic rationale: inhibition of ribonucleotide reductase, the enzymatic machinery cancer cells use to sustain DNA synthesis and blunt gemcitabine’s effect.
The strategy emerged from AI-guided structure-based repurposing, but the translational arc did not stop at a computer screen. Molecular dynamics modeling suggested sitagliptin could disrupt gemcitabine-RRM1/2 interactions, suppress RRM1/2 expression, and restore chemosensitivity across pancreatic cancer cell lines, patient-derived organoids, and mouse models. In practical terms, this matters because gemcitabine depends on a vulnerable nucleotide metabolism axis; if tumor cells can no longer maintain that axis, the drug regains leverage.
Preclinical biology pointed to a metabolic weakness in the tumor
Ribonucleotide reductase sits at the center of deoxynucleotide production, and pancreatic cancer has exploited that pathway for survival under chemotherapy pressure. By interfering with RRM1/2, sitagliptin appears to strike at a metabolic dependency rather than a single surface receptor or signaling node. That approach may be especially relevant in PDAC, a disease notorious for redundancy in growth pathways and rapid adaptation under treatment stress.
The preclinical package extended beyond gemcitabine alone. Sitagliptin enhanced the anti-tumor activity of both gemcitabine-nab-paclitaxel and FOLFIRINOX in laboratory and animal models, suggesting the drug may not merely resensitize tumors to one cytotoxic backbone but could amplify broader combination chemotherapy effects. For a disease in which resistance usually arrives early and with little warning, the biological logic is compelling: reduce nucleotide repair capacity, and the tumor loses one of its best defenses against DNA-damaging therapy.
The phase 2 cohort showed meaningful disease control
SITGEM-CARE was a single-center phase 2 trial that enrolled 22 patients with locally advanced or metastatic PDAC. The median age was 65.0 years, 86.4% had ECOG performance status 1, 68.2% had stage IV disease, and 54.5% had liver metastases. Patients received sitagliptin 100 mg orally once daily continuously with gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m² on days 1 and 8 of 21-day cycles.
Among 22 evaluable patients, eight achieved a partial response and 11 had stable disease. The objective response rate was 36.4% with a 95% CI of 17.2–59.3%, and the disease control rate reached 86.4% with a 95% CI of 65.1–97.1%. Tumor shrinkage occurred in 86.4% of patients. In a malignancy where radiographic regression is often scarce and short-lived, that pattern suggests a real interaction between the repurposed agent and standard cytotoxic therapy.
One point is difficult to ignore: the responses were not isolated events. Disease control held across most of the cohort.
Progression-free survival exceeded what is often seen in advanced PDAC
At a median follow-up of 9.9 months, median progression-free survival was 6.6 months with a 95% CI of 4.8–12.4 months. The 6-month and 9-month progression-free survival rates were 63.6% and 43.5%, respectively. Median overall survival was 12.5 months with a 95% CI of 7.8 months to not reached, and 62.9% of patients were alive at 12 months.
Those numbers do not establish a new standard of care on their own, but they do suggest the regimen deserves serious scrutiny. In metastatic PDAC, median survival has historically hovered close to one year even with intensive treatment, so a regimen that keeps disease controlled through the midterm follow-up window raises a clinically relevant question: whether sitagliptin is converting a portion of early chemotherapy resistance into sustained sensitivity.
The mechanism offers a plausible explanation for the clinical pattern. If ribonucleotide reductase activity falls, tumor cells may lose the capacity to rapidly replenish deoxynucleotides after gemcitabine-induced stress. That can translate into a deeper and more durable cytotoxic effect, especially when combined with a regimen already capable of damaging rapidly dividing cells.
Safety signals stayed within a manageable range
Treatment was well tolerated, and no grade 4 or 5 treatment-related adverse events occurred. For a pancreatic cancer population already carrying substantial symptom burden and prior therapy exposure, that is an important signal. A repurposed oral agent that can be layered onto standard chemotherapy without introducing severe additional toxicity has immediate appeal, particularly when the therapeutic index in PDAC is often narrow.
The absence of severe treatment-related toxicity does not prove the combination will remain safe in broader practice, but it strengthens the argument for further testing. A regimen that improves disease control yet preserves deliverability is one of the few realistic paths in pancreatic cancer, where aggressive treatment can fail if toxicity forces early discontinuation.
Why this trial changes the research conversation
SITGEM-CARE is still a small, single-center phase 2 study, and the findings remain hypothesis-generating. Randomized confirmation is essential before sitagliptin can be considered a credible addition to pancreatic cancer treatment outside the research setting. The current data also cannot separate the contribution of sitagliptin from the established activity of gemcitabine and nab-paclitaxel with the precision needed for practice change.
Even so, the study does something rare in PDAC research: it connects a testable mechanism, a repurposed oral drug, and a measurable clinical signal. That alignment matters because pancreatic cancer has been resistant to many broad immunologic and signaling strategies, while nucleotide metabolism remains one of its most exploitable vulnerabilities.
ClinicalTrials.gov lists the study as NCT05947825. The next step is not more speculation; it is a properly powered randomized trial that can determine whether ribonucleotide reductase inhibition with sitagliptin truly changes the course of gemcitabine-treated pancreatic cancer.